Central nervous system tumor

Vial Welcomes Their New Vice President of Central Nervous Systems (CNS), Emma C. Moran

Retrieved on: 
Monday, August 7, 2023

SAN FRANCISCO, Aug. 6, 2023 /PRNewswire/ -- Vial , a global tech-driven CRO providing next-generation clinical trial management services, announced the addition of Emma C. Moran to their team.

Key Points: 
  • SAN FRANCISCO, Aug. 6, 2023 /PRNewswire/ -- Vial , a global tech-driven CRO providing next-generation clinical trial management services, announced the addition of Emma C. Moran to their team.
  • Moran will be the CRO's new VP of Central Nervous Systems (CNS), bringing with her an impressive 28-year track record in the clinical research industry.
  • On joining Vial, Moran said, "I am honored and excited to be part of the talented Vial team.
  • Simon Burns, CEO and Co-Founder of Vial, shared his excitement over Moran joining the team: "We are thrilled to welcome Emma to Vial as our VP of CNS.

IN8bio Announces Positive INB-200 Phase 1 Data Update in Glioblastoma at the 2023 ASCO Annual Meeting

Retrieved on: 
Monday, June 5, 2023

INB-200 continues to exhibit a manageable safety profile with minimal toxicities and repeat dosing demonstrated no change in the toxicity profile.

Key Points: 
  • INB-200 continues to exhibit a manageable safety profile with minimal toxicities and repeat dosing demonstrated no change in the toxicity profile.
  • Company is on track to complete INB-200 Phase 1 study enrollment in 2023 with updated data expected later this year.
  • NEW YORK, June 05, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, announced updated data from the ongoing Phase 1 clinical trial of INB-200 in patients with newly diagnosed glioblastoma multiforme (GBM).
  • The data were featured as one-of-four oral presentations and the only Phase 1 study during the immunotherapy section of the Central Nervous System Tumors session at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting in Chicago, Illinois.

ProCure Welcomes Board-certified Radiation Oncologist

Retrieved on: 
Thursday, April 27, 2023

SOMERSET, N.J., April 27, 2023 /PRNewswire/ -- ProCure Proton Therapy Center welcomes Timothy H. Chen, MD, to a growing list of tri-state physicians with expertise in treating cancer patients with proton therapy.

Key Points: 
  • SOMERSET, N.J., April 27, 2023 /PRNewswire/ -- ProCure Proton Therapy Center welcomes Timothy H. Chen, MD, to a growing list of tri-state physicians with expertise in treating cancer patients with proton therapy.
  • Dr. Chen is a board-certified radiation oncologist and Medical Director of the Central Nervous System (CNS) program at Jersey Shore University Medical Center, where he recently joined the staff.
  • "ProCure is dedicated to increasing access to proton therapy for residents throughout New Jersey and the tri-state area," ProCure President Tom Wang said.
  • As a result, proton therapy reduces radiation exposure of healthy tissues by more than 60 percent.

EQS-News: Secarna Pharmaceuticals and SciNeuro Pharmaceuticals enter into research and option agreement in the field of CNS diseases

Retrieved on: 
Tuesday, March 28, 2023

EQS-News: Secarna Pharmaceuticals GmbH & Co. KG

Key Points: 
  • EQS-News: Secarna Pharmaceuticals GmbH & Co. KG
    The issuer is solely responsible for the content of this announcement.
  • Munich/Martinsried, Germany, March 27, 2023 – Secarna Pharmaceuticals GmbH & Co. KG (“Secarna”), a biopharmaceutical company focusing on the discovery and development of next-generation antisense oligonucleotide (ASO) therapies to address challenging or previously undruggable targets, and SciNeuro Pharmaceuticals (“SciNeuro”), a leader in the discovery and development of innovative therapeutics for the treatment of neurological diseases, today announced the signature of a multi-target research and option agreement.
  • Within the collaboration, the companies will work together to generate novel ASO therapies directed at targets that play a critical role in diseases of the Central Nervous System.
  • “We are looking forward to collaborating with SciNeuro and to combine our industry-leading antisense oligonucleotide platform LNAplus™ with SciNeuro’s strong expertise and capabilities in the field of CNS diseases,” said Alexander Gebauer, M.D., Ph.D., CEO of Secarna Pharmaceuticals.

BIORCHESTRA Pens a Pact Worth up to $861M for Central Nervous System(CNS)-Targeted Polymeric Nanoparticle for Intravenous Delivery of Nucleic Acid Therapies

Retrieved on: 
Monday, March 27, 2023

CAMBRIDGE, Mass. and DAEJEON, South Korea, March 27, 2023 /PRNewswire/ -- BIORCHESTRA, a biotherapeutics company focused on the treatment of rare and degenerative diseases within the Central Nervous System (CNS) by leveraging the Biorchestra Drug Delivery System (BDDS™), which combines targeted cell delivery capabilities and proprietary RNA chemistries to develop first-in-class therapeutics, today announced an exclusive research, option, and licensing agreement with a global biopharmaceutical company focused on developing transformative medicines. The companies will collaborate on an initial target with the option to expand the collaboration to include several additional targets.

Key Points: 
  • The companies will collaborate on an initial target with the option to expand the collaboration to include several additional targets.
  • Commenting on the transaction, Dr. Branden Ryu, Scientific Founder, Chairman, and Chief Executive Officer, said, "We are excited to begin this collaboration with our U.S. partner.
  • Together we will accelerate a development program to deliver transformational new medicines for patients."
  • "Strategic partnerships are an essential element of our global strategy and what will accelerate market access to our breakthrough innovations," Mr. Kim concluded.

Cognitive Research Corporation Appoints Jeff Williams as Executive Chairman Following Growth Equity Transaction

Retrieved on: 
Tuesday, November 1, 2022

ST. PETERSBURG, Fla., Nov. 1, 2022 /PRNewswire/ -- Cognitive Research Corporation ("CRC") a leading, full-service, therapeutically-focused Contract Research Organization (CRO) specializing in the Central Nervous System (CNS) sector, is pleased to announce that Jeff Williams has been appointed as Executive Chairman of the Board of Directors following the recent close of a growth equity investment from healthcare-focused private equity firm, RC Capital.

Key Points: 
  • ST. PETERSBURG, Fla., Nov. 1, 2022 /PRNewswire/ -- Cognitive Research Corporation ("CRC") a leading, full-service, therapeutically-focused Contract Research Organization (CRO) specializing in the Central Nervous System (CNS) sector, is pleased to announce that Jeff Williams has been appointed as Executive Chairman of the Board of Directors following the recent close of a growth equity investment from healthcare-focused private equity firm, RC Capital.
  • Mr. Williams brings more than 30 years of life science experience to CRC, including significant leadership experience in the CRO industry.
  • "I have known Jeff for more than a decade and we are very excited to have him join the CRC team," says C.G.
  • Cognitive Research Corporation's mission is to support innovative companies developing new medicines and therapies to improve mental health and neurological disorders.

Guerbet announces U.S. Food and Drug Administration (FDA) approval of Elucirem™ (Gadopiclenol)

Retrieved on: 
Wednesday, September 21, 2022

VILLEPINTE, France, Sept. 21, 2022 /PRNewswire/ -- Guerbet (FR0000032526 GBT), a global leader in medical imaging, announced today that the U.S. Food and Drug Administration (FDA) after priority review, approved Elucirem™ (Gadopiclenol), a new macrocyclic GBCA for use in contrast-enhanced magnetic resonance imaging (MRI).

Key Points: 
  • VILLEPINTE, France, Sept. 21, 2022 /PRNewswire/ -- Guerbet (FR0000032526 GBT), a global leader in medical imaging, announced today that the U.S. Food and Drug Administration (FDA) after priority review, approved Elucirem (Gadopiclenol), a new macrocyclic GBCA for use in contrast-enhanced magnetic resonance imaging (MRI).
  • "As a pioneer in MR imaging, thanks to the success of our first gadolinium-based macrocyclic contrast agent, we are delighted with the FDA approval of Elucirem.
  • This approval allows patients and practitioners to benefit from the innovations brought by Elucirem."
  • These factors include those mentioned in the public reports of Guerbet, available on its website www.guerbet.com.

Cell and Gene Therapies Poised to Disrupt Health Care Status Quo With Wave of New Treatments

Retrieved on: 
Thursday, March 31, 2022

Regulatory decisions on 10 new therapies are expected this year, five of which are gene therapies for rare diseases making 2022 perhaps the most impactful year ever for gene therapy.

Key Points: 
  • Regulatory decisions on 10 new therapies are expected this year, five of which are gene therapies for rare diseases making 2022 perhaps the most impactful year ever for gene therapy.
  • But there is significant work ahead of us to ensure that health care systems are ready.
  • The 2019 FDA prediction that it would approve 10-20 cell and gene therapies per year by 2025 is within reach, said Lambert.
  • ARM promotes legislative, regulatory, reimbursement and manufacturing initiatives to advance this innovative and transformative sector, which includes cell therapies, gene therapies and tissue-based therapies.

SOM Biotech granted Orphan Drug Designation by the FDA for SOM3355

Retrieved on: 
Monday, October 18, 2021

SOM Biotech (SOM or the Company), a clinical-stage drug discovery and development company focused on orphan diseases of the Central Nervous System, today announces that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for SOM3355, currently in clinical development for the treatment of chorea movements in Huntingtons Disease (HD).

Key Points: 
  • SOM Biotech (SOM or the Company), a clinical-stage drug discovery and development company focused on orphan diseases of the Central Nervous System, today announces that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for SOM3355, currently in clinical development for the treatment of chorea movements in Huntingtons Disease (HD).
  • Receiving ODD may qualify SOM Biotech for a seven year period of US marketing exclusivity upon approval of SOM3355.
  • Ral Insa, Chief Executive Officer of SOM Biotech highlights: Receiving Orphan Drug Designation for SOM3355 is a significant step forward for Huntingtons Disease patients and confirms the potential of our AI-powered approach to accelerate drug discovery and development.
  • About SOM Biotech: SOM Biotech (www.sombiotech.com) established in 2009 is a biopharmaceutical company based in Barcelona, Spain.

MYND Life Sciences Announces Diagnostic Division with Formation of Wholly-Owned Subsidiary - MYND Diagnostics Ltd.

Retrieved on: 
Thursday, October 7, 2021

VANCOUVER, BC, Oct. 7, 2021 /PRNewswire/ -MYND Life Sciences Inc. (CSE: MYND) (OTC: MYNDF)("MYND" or the "Company") is pleased to announce the formation of its diagnostic biomarker division with the incorporation of a wholly-owned subsidiary, MYND Diagnostics Ltd. ("MYND Diagnostics" or the "Subsidiary").

Key Points: 
  • VANCOUVER, BC, Oct. 7, 2021 /PRNewswire/ -MYND Life Sciences Inc. (CSE: MYND) (OTC: MYNDF)("MYND" or the "Company") is pleased to announce the formation of its diagnostic biomarker division with the incorporation of a wholly-owned subsidiary, MYND Diagnostics Ltd. ("MYND Diagnostics" or the "Subsidiary").
  • The Subsidiary's innovation, enabled by proprietary technology, allows for the quantitative and qualitative measurement of the MYND Anti-inflammatory Peptide ("MAP") biomarker.
  • "We are focused on supporting our drug development pipeline with the formation of MYND Diagnostics Ltd., our diagnostic biomarker division which will generate near term revenue through the commercialization of our MAP biomarker", stated Dr. Lyle Oberg MD, MYND.
  • MYND Life Sciences is a medical biotech drug research and development company focused on neuro-pharmaceutical and novel psilocybin drug development, diagnostics and vaccines.